Sunshine Lake Pharma Co., Ltd. (HKG:6887)

Market Cap	24.05B +173.9%
Revenue (ttm)	5.36B +29.3%
Net Income	303.18M -43.6%
EPS	0.61 -73.6%
Shares Out	575.98M
PE Ratio	68.23
Forward PE	n/a
Dividend	5.69 (12.74%)
Ex-Dividend Date	Jul 31, 2025

Volume	112,200
Average Volume	259,567
Open	41.76
Previous Close	41.76
Day's Range	41.28 - 41.92
52-Week Range	39.80 - 67.30
Beta	-0.10
RSI	43.64
Earnings Date	Aug 28, 2026

About Sunshine Lake Pharma

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 6,353
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6887

Financial Performance

In 2025, Sunshine Lake Pharma's revenue was 4.82 billion, an increase of 29.31% compared to the previous year's 3.72 billion. Earnings were 272.44 million, a decrease of -43.56%.

Financial numbers in CNY